InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (115)	7/26/2001 7:02:02 PM
From: Biomaven	Read Replies (1) of 508

IJ, Of course relevant to this is today's approval of Rebetol (ribavirin) in its own right (not in the Intron combo, but still meant to be combined with Intron). Looking around on the net, there is some discussion of the Infergen+ribavirin combo: However, Dr. Fong suggests ribavirin may have a role in combination with other interferons besides Intron A. "One combination that I think would be of great interest is Infergen and ribavirin because Infergen does seem to be a little different than Intron A and Roferon," he says. hepcresearch.com hepcresearch.com pslgroup.com and this interesting article on the "unbundling" of Rebetron: aidsinfonyc.org Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next